Lilly Sees Profit Lifted by Newer Drugs  NEW YORK (Reuters) - Eli Lilly and Co. &lt;A HREF="http://www.investor.reuters.com/FullQuote.aspx?ticker=LLY.N target=/stocks/quickinfo/fullquote"&gt;LLY.N&lt;/A&gt; on Thursday  said it expects earnings in 2005 to rise to between \$3.05 and  \$3.15 per share before special items as growing sales of newer  medicines more than offset disappointing sales of its  top-selling schizophrenia drug.